Last edition
News about "tradipitant"
FDA Lifts Partial Clinical Hold on Vanda's Tradipitant for Motion Sickness
The lift allows Vanda to extend clinical studies of tradipitant in motion sickness. Meanwhile, the review of the fully completed New Drug Application for tradipitant for the prevention of vomiting induced by motion remains on track.
Tradipitant | 05/12/2025 | By Dineshwori | 259
Vanda's Tradipitant Shows Strong Efficacy in Preventing Wegovy-Induced Nausea and Vomiting
Vanda Pharmaceuticals has announced positive topline results from its randomised controlled study evaluating tradipitant, an oral neurokinin-1 (NK-1) receptor antagonist, for preventing nausea and vomiting associated with GLP-1 receptor agonist Wegovy in overweight and obese adults.
Tradipitant | 18/11/2025 | By Dineshwori | 195
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy